• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000

    4/4/24 10:02:07 AM ET
    $ALUR
    $EFTR
    $KWE
    $KYCH
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALUR alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday.

    Following the market opening Thursday, the Dow traded up 0.34% to 39,259.15 while the NASDAQ rose 0.85% to 16,411.43. The S&P 500 also rose, gaining, 0.67% to 5,246.15.

    Check This Out: Insiders Buying Walgreens And 2 Other Stocks

     

    Leading and Lagging Sectors

     

    Real estate shares jumped by 1.2% on Thursday.

    In trading on Thursday, energy shares rose by just 0.2%.

     

    Top Headline

     

    U.S. initial jobless claims rose by 11,000 from the previous week’s revised reading to 221,000 on March, the most in two months.

     

    Equities Trading UP

     

    TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares shot up 118% to $2.85. TCBP announced execution of non-binding letter of intent for acquisition of NK Platform Technologies.

    Shares of Allurion Technologies Inc. (NASDAQ:ALUR) got a boost, surging 61% to $2.78 after the company announced the commercial availability of its Virtual Care Suite in the United States. Also, Chardan Capital initiated coverage on the stock with a Buy rating and announced a $5 price target.

    Tevogen Bio Holdings Inc. (NASDAQ:TVGN) shares were also up, gaining 55% to $3.96. Tevogen Bio, on Wednesday, appointed Tapan V Shah as Head of Investor Relations and Corporate Development.

     

    Equities Trading DOWN

     

    eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) shares dropped 83% to $2.76. The company announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer.

    Shares of Keyarch Acquisition Corporation (NASDAQ:KYCH) were down 36% to $5.83.

    KWESST Micro Systems Inc. (NASDAQ:KWE) was down, falling 29% to $0.8026 after the company announced a proposed US public offering.

    Also Check This Out: Top 3 Real Estate Stocks That Are Ticking Portfolio Bombs

     

    Commodities

     

    In commodity news, oil traded down 0.3% to $85.16 while gold traded down 0.4% at $2,305.40.

    Silver traded down 0.6% to $26.91 on Thursday, while copper rose 0.5% to $4.2155.

     

    Euro zone

     

    European shares were mostly higher today. The eurozone’s STOXX 600 rose 0.3%, London’s FTSE 100 rose 0.6% while Spain’s IBEX 35 Index rose 0.6% The German DAX rose 0.2% French CAC 40 rose 0.1% while Italy’s FTSE MIB Index fell 0.1%.

    Industrial producer prices in the eurozone fell by 1.0% from the prior month in February compared to a 0.9% decline in the prior month, while services PMI climbed to 51.5 in March versus 50.2 in the earlier month.

    The HCOB France services PMI fell to 48.3 in March versus 48.4 a month ago, while German services PMI rose to 50.1 in March versus a preliminary reading of 49.8. The S&P Global UK services PMI fell to 53.1 in March versus 53.8 in the prior month.

     

    Asia Pacific Markets

     

    Asian markets closed higher on Thursday, with Japan’s Nikkei 225 gaining 0.81% and India’s S&P BSE Sensex rising 0.5%.

    The HSBC Indian services PMI rose to 61.2 in March versus a preliminary reading of 60.3 and compared to a final reading of 60.6 in the prior month.

     

    Economics

     

    U.S. jobless claims rose by 11,000 from the previous week’s revised reading to 221,000 on March, the most in two months.

    U.S. trade deficit increased to $68.9 billion in February versus a revised $67.6 billion gap in the previous month.

    Now Read This: Levi Strauss, Conagra Brands And 3 Stocks To Watch Heading Into Thursday

    Get the next $ALUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALUR
    $EFTR
    $KWE
    $KYCH

    CompanyDatePrice TargetRatingAnalyst
    Tevogen Bio Holdings Inc.
    $TVGN
    3/4/2025$10.00Buy
    D. Boral Capital
    Allurion Technologies Inc.
    $ALUR
    11/14/2024Buy → Neutral
    Chardan Capital Markets
    Allurion Technologies Inc.
    $ALUR
    10/2/2024$2.00Buy
    TD Cowen
    Allurion Technologies Inc.
    $ALUR
    9/6/2024$2.00Buy
    ROTH MKM
    Allurion Technologies Inc.
    $ALUR
    2/9/2024$5.00Buy
    Jefferies
    eFFECTOR Therapeutics Inc.
    $EFTR
    1/25/2022$20.00 → $16.00Outperform
    Credit Suisse
    eFFECTOR Therapeutics Inc.
    $EFTR
    1/25/2022$20.00 → $6.20Buy → Hold
    Stifel
    eFFECTOR Therapeutics Inc.
    $EFTR
    1/25/2022$33.00 → $8.00Market Outperform
    JMP Securities
    More analyst ratings

    $ALUR
    $EFTR
    $KWE
    $KYCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Tevogen Bio with a new price target

    D. Boral Capital initiated coverage of Tevogen Bio with a rating of Buy and set a new price target of $10.00

    3/4/25 8:26:08 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allurion Technologies downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded Allurion Technologies from Buy to Neutral

    11/14/24 8:29:33 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Allurion Technologies with a new price target

    TD Cowen initiated coverage of Allurion Technologies with a rating of Buy and set a new price target of $2.00

    10/2/24 7:13:57 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    $EFTR
    $KWE
    $KYCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Saadi Ryan H. gifted 50,000 shares, decreasing direct ownership by 0.04% to 124,284,453 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    12/22/25 5:43:21 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Desai Kirti gifted 300,000 shares, decreasing direct ownership by 3% to 10,149,186 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    12/15/25 5:31:50 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Saadi Ryan H. gifted 460,000 shares, decreasing direct ownership by 0.37% to 124,334,453 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    12/12/25 6:51:18 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALUR
    $EFTR
    $KWE
    $KYCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gaur Shantanu bought $24,484 worth of shares (8,000 units at $3.06), increasing direct ownership by 100% to 16,000 units (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    5/21/25 4:15:08 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Gaur Shantanu bought $26,800 worth of shares (8,000 units at $3.35) (SEC Form 4)

    4 - ALLURION TECHNOLOGIES, INC. (0001964979) (Issuer)

    4/1/25 4:15:07 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

    4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)

    6/13/24 4:30:24 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALUR
    $EFTR
    $KWE
    $KYCH
    SEC Filings

    View All

    Tevogen Bio Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    1/30/26 3:37:38 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Tevogen Bio Holdings Inc.

    DEF 14A - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    1/26/26 5:29:39 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Allurion Technologies Inc.

    EFFECT - ALLURION TECHNOLOGIES, INC. (0001964979) (Filer)

    1/20/26 12:15:36 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    $EFTR
    $KWE
    $KYCH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices

    Through Bionut, a leader in obesity care in Argentina, Allurion Program patients will now have access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced a partnership with Bionut, a leader in obesity care in Argentina, and Farmastar, a local pharmacy partner with access to the official supplier of Mounjaro (tirzepatide) in Argentina, to provide patients with access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule. "The obesity epidemic is growing, and patients are in need of more therapeutic options," said Romina Sapir, Di

    2/3/26 9:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

    WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company's future financial performance, capital requirements, compliance with applicable solvency laws, including under the Delaware General Corporation Law, and final approval by the Board of Directors aft

    1/30/26 3:00:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

    WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones including revenue. The updated program will be applicable to all employees, officers, directors and consultants who are eligible to participate in the Company's long term incentives plan. Tevogen Founder and CEO, Dr. Ryan Saadi, commented, "Tevogen began as a T cell therapy biotech and has since evolved into a diversified healthcare company, including a scalable healthcare AI initiative. The Company's goal is

    1/29/26 2:45:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALUR
    $EFTR
    $KWE
    $KYCH
    Financials

    Live finance-specific insights

    View All

    Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

    WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company's future financial performance, capital requirements, compliance with applicable solvency laws, including under the Delaware General Corporation Law, and final approval by the Board of Directors aft

    1/30/26 3:00:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update

    Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update. Recent Company Highlights Successfully passed U.S. Food and Drug Administration ("FDA") Pre-Approval Inspection and Bioresearch Monitoring (BIMO) audit with zero observations and no Form 483 issued Completed Premarket Approval ("PMA") Acceptance and Filing Reviews, entered Substantive Review for the Allurion Smart Capsule and successfully completed Day-100 meeting Entered into transaction to exchange all outstanding debt for convertible preferred equity and concurrently announced private placement fina

    11/12/25 8:00:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing

    Passing of key audits with zero findings and completion of Day-100 meeting are significant milestones in the FDA PMA process as the Company enters final stages of FDA review process for its Allurion Smart Capsule Exchange of outstanding debt for shares of convertible preferred stock would result in Company being debt-free $5M private placement financing with participation from new and existing stockholders and a strategic partner with deep obesity expertise significantly strengthens Company's financial position as the Company seeks FDA approval Allurion Technologies, Inc. (NYSE:ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced it has

    11/11/25 8:45:00 AM ET
    $ALUR
    Medical/Dental Instruments
    Health Care

    $ALUR
    $EFTR
    $KWE
    $KYCH
    Leadership Updates

    Live Leadership Updates

    View All

    Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

    WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025. The Startup Forum will feature insights from venture capital leaders and early-stage innovators on how they are scaling their companies with Databricks. Mehta will join industry peers including Chris Gervais, CTO of Codametrix, and Stavros Papadopoulos, CEO of TileDB, in a discussion moderated by Tony Pezzullo, Principal at SignalFire. Mehta will share perspectives on Te

    9/10/25 11:59:02 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

    WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

    4/29/25 8:00:00 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

    WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ's Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at Morgan Lewis. Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, J.P. Morgan Private Bank, Amanda Laskey, Life Sciences Senior Analyst, RSM US, and Kee Colon, MBA, Managing Director, Cantor Fitzgerald. The conference, held on May 13, 2025,

    4/14/25 1:53:50 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALUR
    $EFTR
    $KWE
    $KYCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by KWESST Micro Systems Inc.

    SC 13G - KWESST Micro Systems Inc. (0001889823) (Subject)

    11/14/24 5:34:02 PM ET
    $KWE
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

    SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    11/14/24 5:29:01 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Allurion Technologies Inc.

    SC 13G/A - ALLURION TECHNOLOGIES, INC. (0001964979) (Subject)

    11/14/24 4:43:43 PM ET
    $ALUR
    Medical/Dental Instruments
    Health Care